Abbott India Ltd(ABBOTINDIA)

NSE: ABBOTINDIABSE: 500488

₹ 25,004.3-1.53%refreshed 23 Oct, 03:50 pm ISTMarket cap: ₹ 53,132 crWebsite: www.abbott.co.in/Updated: 24 Oct 2026

About

Abbott India Ltd is a pharmaceutical company that has operated in India for over 80 years, selling branded prescription and over-the-counter medicines across therapeutic areas including Gastroenterology, Women's Health, Metabolics, CNS, Vaccines, and Multi-Specialty. The company reported revenue of Rs 6,929.05 Cr in FY26 and has consistently grown above the Indian Pharmaceutical Market. Sixteen of its brands rank #1 or #2 in their participated markets, and 8 brands feature in the Top 100 of the Indian Pharmaceutical Market.^[1][2]

Business segments

Abbott India operates in a single 'Pharmaceuticals' segment covering Gastroenterology, Women's Health, Metabolics, Central Nervous System, Vaccines, and Multi-Specialty therapeutic areas.^[1]

Products and brands

The portfolio comprises 130+ products across its therapeutic areas as of FY25.^[1]
Flagship Gastroenterology brands include Udiliv, Duphalac, Cremaffin Plus, Digene, and Creon; the GI portfolio grew 15.9% in FY 2024-25.^[1]
Duphaston is the #1 brand in the Women's Health dydrogesterone segment; Women's Health faced generic competition headwinds in FY 2024-25.^[1]
CNS portfolio grew 3.2% in FY 2024-25 led by Vertin; Multi-Specialty grew 5.8% with key brands Zolfresh, Arachitol portfolio, Brufen, and Duvadilan.^[1]
7 new products were launched in FY 2024-25, including Vonefi (June 2024), Digeraft Tablet (September 2024), and Digene On The Go (March 2025).^[1]

Market position

16 brands rank #1 or #2 in their respective participated markets, and 10 brands rank in the Top 300 of the Indian Pharmaceutical Market, as of FY25.^[1]
8 brands feature in the Top 100 of the Indian Pharmaceutical Market as of FY25.^[1]
Top brands outpacing market growth include Udiliv, Duphalac, Cremaffin Plus, Digene, Creon, Ganaton, Heptral, Colospa, and Digeraft in FY 2024-25.^[1]

Manufacturing

Abbott India has one manufacturing plant located in Goa, which accounts for 24.3% of net sales as of FY25; the balance is sourced externally.^[1]

Innovation and R&D

Abbott India's innovation and development centre is located in Mumbai; it developed Digeraft tablets as the first to bring the product to the Indian market.^[1]
The company managed 15 clinical studies with 22 publications in scientific journals in FY 2024-25, all conducted in compliance with Good Clinical Practice.^[1]
Abbott India partnered with Takeda to launch Vonoprazan (Vonefi), a new class drug for GERD in the Potassium-Competitive Acid Blocker segment, among the first in India in June 2024.^[1]

Distribution and reach

Abbott India reaches 40,000+ pharmacies and 75,000+ healthcare professionals (HCPs) through its customer engagement programmes as of FY25.^[1]

Long-term track record

Over 80 years in operation; 10-year CAGR of 9.3% for Revenue from Operations, 16.9% for EBITDA, and 18.7% for PAT through FY25.^[1]

Market Cap

₹53,132 Cr

High / Low

₹30,598 / 24,670

Stock P/E

32.9

Price / Book

11.1

Book Value

₹2,247

EPS

₹730.4

No. of Shares

2.12 Cr

ROCE

45.3%

ROE

34.5%

OPM

29.2%

Debt / Equity

0.00

Sales

₹6,929 Cr

Net Profit

₹1,552 Cr

Promoter holding

75.0%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials